India’s pharma firms investing more in the biotech segment

Several Indian pharma firms are investing more in their biotechnology businesses. For example, Biocon has invested over $200 million in its insulin manufactring unit in Malaysia. Lupin and Wockhardt are also investing more in order to produce new insulins and biosimilar drugs.

Read the source article at Business Standard